8 Apr 2025 • A recent study tracking 2,825 atrial fibrillation patients has raised concerns over unregulated non-vitamin K antagonist oral anticoagulants (NOACs) dosing, revealing that overdosing is associated with significantly higher mortality rates.

Those receiving excessive NOAC doses had higher mortality at 24 months (18.75 vs.10.92) events/patient-year) and 60 months (10.00 vs. 6.49) compared to standard and underdosing groups. Additionally, overdosing led to a higher rate of composite endpoint events, such as stroke and major bleeding.

Age, anemia and renal insufficiency further elevated these risks, suggesting the need for more precise and regulated anticoagulant management, particularly for older patients and those with other comorbidities.

Source: BMC Cardiovascular Disorders | Read Full Story